Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Govt and industry fund health and biotech innovation in SEQ
The SEQ Innovation Economy Fund has awarded eight projects $94m in government funding, while...
Does the 2025–26 Budget do enough for science?
AAMRI has described the 2025–26 federal Budget as "very disappointing" for the...
Ming Long appointed Chair of CSIRO
Minister for Industry and Science Ed Husic has announced the appointment of Ming Long to the role...
